The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…


Diabetes DTC advertising skyrockets as Novo, Sanofi and Lilly vie for share

Novo Nordisk sees unexpected China rebound in Q2, but no word on Tresiba

Fresh off its win in CV outcomes trial, Victoza falls short in heart failure study